The Phase 3 study (NCT02684292) investigating pembrolizumab (Keytruda) for participants with relapsed or refractory Classical Hodgkin Lymphoma completed its primary data collection on 2026-01-14. This trial, known as KEYNOTE-204, compared pembrolizumab to brentuximab vedotin.
Background
Pembrolizumab (Keytruda) was investigated in participants with relapsed or refractory Classical Hodgkin Lymphoma. The study compared its efficacy against brentuximab vedotin.
Trial design
The KEYNOTE-204 study (NCT02684292) was a Phase 3, randomized trial that enrolled 304 participants. The study evaluated pembrolizumab (MK-3475) in participants with relapsed or refractory Classical Hodgkin Lymphoma. Participants were randomized to receive either pembrolizumab or brentuximab vedotin for up to 35 three-week cycles. The primary hypotheses of the study were that pembrolizumab prolongs Progression-free Survival (PFS) and Overall Survival (OS) compared to brentuximab vedotin.
What this means
The primary completion of the KEYNOTE-204 trial signifies that the main data collection phase for this Phase 3 study has concluded. Clinical researchers will now proceed with data analysis to evaluate the primary endpoints of Progression-free Survival and Overall Survival for pembrolizumab compared to brentuximab vedotin in relapsed or refractory Classical Hodgkin Lymphoma. The results of this study will be crucial for understanding the potential role of pembrolizumab in this patient population.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT02684292, titled "Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)," was posted on 2026-01-14 on clinicaltrials.gov.